Company Description
20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD.
That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab.
| Country | United States |
| Founded | 2000 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Jonathan Cohen |
Contact Details
Address: 15810 Gaither Road, Suite 235 Gaithersburg, MD 20877 United States | |
| Phone | 240-453-6339 |
| Website | 2020biolabs.com |
Stock Details
| Ticker Symbol | AIDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1139685 |
| Employer ID | 52-2272107 |
| SIC Code | 8734 |
Key Executives
| Name | Position |
|---|---|
| Jonathan Cohen | Chief Executive Officer, President and Director |
| Alan B. Bergman | Chief Financial Officer |
| Jiming Zhou, Ph.D. | Chief Operating Officer |
| Ron Baker | Chief Business Officer |
| Michael Lebowitz, Ph.D. | Chief Scientific Officer |
| John G. Compton, Ph.D. | Chairman of the Board |
| Richard M. Cohen | Director |
| Wei Lu | Director |
| Prasanth Reddy | Director |
| John W. Rollins | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2025 | 1-K/A | Filing |
| Dec 18, 2025 | 1-U | Current Report Pursuant to Regulation A |
| Dec 12, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 12, 2025 | C/A | Filing |
| Nov 26, 2025 | C/A | Filing |
| Nov 21, 2025 | 1-U | Current Report Pursuant to Regulation A |
| Nov 4, 2025 | C/A | Filing |
| Oct 30, 2025 | C | Filing |
| Sep 22, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 13, 2025 | C-U | Filing |